Search 
Saturday, July 26, 2008 ..:: Protocols » CTN Protocol ::.. Register  Login
 Clinical Trials Network Protocol Listing Minimize

Below is a listing of protocols available to Network members. CTN members may request any of the protocols below by completing a study request form. Some protocols may already have active CTN members participating in the study. All participating centers are posted in the right column.

For CTN members or other insitutions with an active confidentiality disclosure agreement in place, you may see a table below for protocols in development that are available to investigators to assess their interest in the trial. If you do not see this table, you may contact the Network office to request access.

All Protocol documents are available for viewing by clicking on the protocol hyperlinks. If you are an CTN Member listed on your institution's Delegation of Authority or a multicenter authorized user, you will have access to the the full protocol documents.  If wish to gain access to particular trial, please contact the Network office at hccrnet@musc.edu or 843-792-1753. Thank you!


 Print   
 Protocols Available for CTN Activation and Enrollment Minimize

last updated July 8, 2008

Disease Site

CTO

Protocol Title

Participating Centers

GU
100822
VELCADE (bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer 
Hollings Cancer Center
South Carolina Oncology Associates
Spartanburg Regional Healthcare System
Loma Linda University
 University of California-Irvine (pending)
GU
100892
A Phase II Study of Neoadjuvant Cisplatin, Gemcitabine, and Bevacizumab Followed by Radical Cystectomy for Patients with Muscle Invasive Resectable Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder
Hollings Cancer Center
Lowcountry Hematology and Oncology (pending)
GI
100918
Phase II Study of Neoadjuvant Gemcitabine, Oxaliplatin and Cetuximab followed by Surgery or Concurrent External Beam Radiation with Capecitabine for Patients with Locally Advanced Unresectable Non-Metastatic Pancreatic Cancer
 
Hollings Cancer Center
McLeod Regional Medical Center 
(pending)
Spartanburg Regional Healthcare System
Lowcountry Hematology and Oncology (pending)
HN
100949
Multicenter Randomized Phase II Study of Erlotinib Cisplatin and Radiotherapy versus Cisplatin and Radiotherapy in Patients with Stage III and IV Squamous Cell Carcinoma of the Head and Neck
Hollings Cancer Center
McLeod Regional Medical Center
Spartanburg Regional Healthcare System
Breast
101072
Phase II Study of Neoadjuvant Treatment with Novelos-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel in Patient with Stage IIB -IIIC Breast Cancer
Hollings Cancer Center
University of Miami (pending)
GU   
101098
A Phase I/II Trial of Bortezomib and Bevacizumab ("BB-mib-mab") in Patients with Advanced or Recurrent Renal Cell Cancer (RCC) with Assessment of Tissue Correlates of Response
Hollings Cancer Center
GU   
101137 
A Phase II Trial of Dasatinib (Sprycel) in Subjects with Hormone-Refractory Prostate Cancer, Previously Treated with Chemotherapy
Hollings Cancer Center
Spartanburg Regional Healthcare System
Thoracic   
101240 
A Phase 2 Exploratory Study of Erlotinib and XXX in Patients with Non-small Cell Lung Carcinoma who are Progressing on Erlotinib
Hollings Cancer Center
South Carolina Oncology Associates
Thoracic   
101266 
Randomized, Double-Blinded Phase II Trial of Esomeprazole versus Esomeprazole Two Doses of Aspirin in Barrett's Esophagus Patients
MUSC Digestive Disease Center
Spartanburg Regional Healthcare System

 


 Print   
 CTN Studies and Reference Numbers Minimize

 Print   
 Protocols Closed to Enrollment Minimize

Below are protocols that were closed to enrollment but have patients still in follow-up.

Date of Closure
CTO
Protocol Title
July 19, 2007
100829
A Phase II Study of XELOX in Locally Advanced or Metastatic Gastric Cancer
May 30, 2008
101109
Phase I Azacitidine with Rituximab, Vincristine and Cyclophosphamide in Refractory Follicular Non-Hodgkin's Lymphoma

 


 Print   
Copyright 2008 by Hollings Cancer Center   Terms Of Use  Privacy Statement